#12 1636

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Marvin Slepian

Serial No.: 10/072,766 Art Unit: 1636

Filed: February 8, 2002 Examiner: Not Yet Assigned

For: *ENDOMURAL THERAPY*

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits an Information Disclosure Statement, including four (4) pages of Form PTO-1449 and a copy of each document cited therein.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S. Patents

Number	Issue Date	Patentee	Class/Subclass
2,677,700	05-04-1954	Jackson et al.	260-488
3,036,118	05-22-1962	Jackson et al.	260-484
3,535,307	10-20-1970	Moss et al.	260-209
3,829,506	08-13-1974	Schmolka et al.	260-615 B
4,517,686	05-21-1985	Ruoslahti et al.	3/1
4,578,079	03-25-1986	Ruoslahti et al.	623/11
4,589,881	05-20-1986	Pierschbacher et al.	623/11

4,938,763	07-03-1990	Dunn et al.	604/891.1
5,041,380	08-20-1991	Ruoslahti et al.	435/240.2
5,149,780	09-22-1992	Plow et al.	530/324
5,169,930	12-08-1992	Ruoslahti et al.	530/35

Publications

AUMAILLEY, et al., "Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1," *FEBS*, 291(1): 50-54 (1991).

BECK, et al., "Structure and function of laminin: anatomy of a multidomain glycoprotein," *FASEB J.*, 4(2):148-160 (1990).

GRAF, et al., "A pentapeptide from the laminin B1 chain mediates cell adhesion and binds the 67,000 laminin receptor," *Biochem.*, 26(22):6896-6900 (1987).

GRAF, et al., "Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding," *Cell*, 48(6):989-996 (1987).

GRANT, et al., "Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro," *Cell*, 58(5):933-943 (1989).

GURRATH, et al., "Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides," *Eur. J. Biochem.*, 210(3) 911-921 (1992).

IWAMOTO, et al., "YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation," *Science*, 238(4830):1132-1134 (1987).

KAUFMANN, "Heat shock proteins and the immune response," *Immunol. Today*, 11(4):129-137 (1990).

KLEINMAN, et al., "Basement membrane complexes with biological activity," *Biochem.*, 25(2):312-318 (1986).

KLEINMAN, et al., "Biological activities of laminin," *J. Cell Biochem.*, 27(4):317-325 (1985).

LINDQUIST, "The heat-shock response," *Ann. Rev. Biochem.*, 55:1151-1191 (1986).

LINDQUIST, et al., "The heat-shock proteins," *Annu. Rev. Genet.*, 22:631-677 (1988).

MOHRI, et al., "Novel effect of cyclicization of the Arg-Gly-Asp-containing peptide on vitronectin binding to platelets," *Amer. J. Hem.*, 37(1):14-19 (1991).

MORIMOTO, "Heat shock: the role of transient inducible responses in cell damage, transformation, and differentiation," *Cancer Cells*, 3(8):295-301 (1991).

NOVER, "HSFs and HSPs - a stressful program on transcription factors and chaperones." Stress Proteins, and the Heat Shock Response, sponsored by Cold Spring Harbor Laboratory (Cold Spring Harbor, NY USA April 29-May 2, 1991) *New Biol.* 3:855-859 (1991).

NOVER, et al., "Heat shock protein, in Heat Shock Response (CRC Press, 1991) pp. 41-127.

PELHAM, "Heat shock and the sorting of luminal ER proteins," *EMBO J.*, 8(11):3171-3176 (1989).

PELHAM, "Speculations on the functions of the major heat shock and glucose-regulated proteins," *Cell*, 46(7): 959-961 (1986).

PIERSCHBACHER, et al., "Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion," *J. Biol. Chem.*, 262(36): 17294-17298 (1987).

SAKAMOTO, et al., "Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2," *Cancer Res.*, 51(3):903-906 (1991).

SCARBOROUGH, et al., "Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa," *J. Biol. Chem.* 268(2): 1066-1073 (1993).

SCHLESINGER, "Heat shock proteins," *J. Biol. Chem.*, 265(21):12111-12114 (1990).

SCHLESINGER, Heat Shock: from bacterial to man (Cold Spring Harbor, Cold Spring Harbor, NY 1982).

TAY, et al., "Activity toward thrombin-antithrombin of heparin immobilized on two hydrogels," *Biomaterials*, 10(1): 11-15 (1989).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: June 21, 2002

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com



Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: June 21, 2002

Brent A. Winitt

ATL1 #528203 v1

Please type a plus sign (+) inside this box → [+]

RECEIVED
JUL 3 2002
TECH CENTER 1600/2900

PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/072,766
Filing Date	February 8, 2002
First Named Inventor	Marvin Slepian
Group Art Unit	1636
Examiner Name	
Attorney Docket Number	MJS 104

Sheet 1 of 4

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	US Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		2,677,700		Jackson et al.	05-04-1954	
		3,036,118		Jackson et al.	05-22-1962	
		3,535,307		Moss et al.	10-20-1970	
		3,829,506		Schmolka et al.	08-13-1974	
		4,517,686		Ruoslahti et al.	05-21-1985	
		4,578,079		Ruoslahti et al.	03-25-1986	
		4,589,881		Pierschbacher et al.	05-20-1986	
		4,938,763		Dunn et al.	07-03-1990	
		5,041,380		Ruoslahti et al.	08-20-1991	
		5,149,780		Plow et al.	09-22-1992	
		5,169,930		Ruoslahti et al.	12-08-1992	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office.[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

Examine Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

[1] Unique citation designation number [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	10/072,766
Filing Date	February 8, 2002
First Named Inventor	Marvin Slepian
Group Art Unit	1636
Examiner Name	
Attorney Docket Number	MJS 104

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		KUMAILLEY, et al., "Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1," *FEBS*, 291(1): 50-54 (1991).	
		BECK, et al., "Structure and function of laminin: anatomy of a multidomain glycoprotein," *FASEB J.*, 4(2):148-160 (1990).	
		GRAF, et al., "A pentapeptide from the laminin B1 chain mediates cell adhesion and binds the 67,000 laminin receptor," *Biochem.*, 26(22):6896-6900 (1987).	
		GRAF, et al., "Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding," *Cell*, 48(6):989-996 (1987).	
		GRANT, et al., "Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro," *Cell*, 58(5):933-943 (1989).	
		GURRATH, et al., "Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides," *Eur. J. Biochem.*, 210(3) 911-921 (1992).	
		IWAMOTO, et al., "YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation," *Science*, 238(4830):1132-1134 (1987).	
		KAUFMANN, "Heat shock proteins and the immune response," *Immunol. Today*, 11(4):129-137 (1990).	
		KLEINMAN, et al., "Basement membrane complexes with biological activity," *Biochem.*, 25(2):312-318 (1986).	
		KLEINMAN, et al., "Biological activities of laminin," *J. Cell Biochem.*, 27(4):317-325 (1985).	

Examiner's Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	10/072,766
Filing Date	February 8, 2002
First Named Inventor	Marvin Slepian
Group Art Unit	1636
Examiner Name	
Attorney Docket Number	MJS 104

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		LINDQUIST, "The heat-shock response," *Ann. Rev. Biochem.*, 55:1151-1191 (1986).	
		LINDQUIST, et al., "The heat-shock proteins," *Annu. Rev. Genet.*, 22:631-677 (1988).	
		MOHRI, et al., "Novel effect of cyclicization of the Arg-Gly-Asp-containing peptide on vitronectin binding to platelets," *Amer. J. Hem.*, 37(1):14-19 (1991).	
		MORIMOTO, "Heat shock: the role of transient inducible responses in cell damage, transformation, and differentiation," *Cancer Cells*, 3(8):295-301 (1991).	
		NOVER, "HSFs and HSPs - a stressful program on transcription factors and chaperones." Stress Proteins, and the Heat Shock Response, sponsored by Cold Spring Harbor Laboratory (Cold Spring Harbor, NY USA April 29-May 2, 1991) *New Biol.* 3:855-859 (1991).	
		NOVER, et al., "Heat shock protein, in Heat Shock Response (CRC Press, 1991) pp. 41-127.	
		PELHAM, "Heat shock and the sorting of luminal ER proteins," *EMBO J.*, 8(11):3171-3176 (1989).	
		PELHAM, "Speculations on the functions of the major heat shock and glucose-regulated proteins," *Cell*, 46(7): 959-961 (1986).	
		PIERSCHBACHER, et al., "Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion," *J. Biol. Chem.*, 262(36): 17294-17298 (1987).	
		SAKAMOTO, et al., "Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2," *Cancer Res.*, 51(3):903-906 (1991).	

Examiner's Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	10/072,766
Filing Date	February 8, 2002
First Named Inventor	Marvin Slepian
Group Art Unit	1636
Examiner Name	
Attorney Docket Number	MJS 104

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		✓ CARBOROUGH, et al., "Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa," *J. Biol. Chem.* 268(2): 1066-1073 (1993).	
		✓ SCHLESINGER, "Heat shock proteins," *J. Biol. Chem.*, 265(21):12111-12114 (1990).	
		✓ SCHLESINGER, Heat Shock: from bacterial to man (Cold Spring Harbor, Cold Spring Harbor, NY 1982).	
		✓ TAY, et al., "Activity toward thrombin-antithrombin of heparin immobilized on two hydrogels," *Biomaterials*, 10(1): 11-15 (1989).	

Examiner's Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+